Follow up of severe adverse effects supposedly attributable to vaccination or immunization reported to the Ministry of Public Health between 2010 and 2014
Abstract
Introduction: adverse events supposedly attributable to vaccination or immunization are negative events that follow immunization and may be attributed to it. The study aimed to characterize and follow up severe adverse effects reported to the National Pharmacovigilance System of the Ministry of Public Health during 2010-2014.
Method: a transversal study of the evolution of the individuals affected was performed by means of a telephone survey. Variables used to characterize possible complications were the following: treatment required, time until recovery, type of recovery, disability and death. Behavior upon the following vaccination was also evaluated. Definitions from Brighton Collaboration and the World Health Organization were used to describe the events.
Results: 107 cases of severe events were reported between 2010 and 2014, which corresponded to 79 individuals, 53 of which were analysed. Most of the severe events were associated to neurological disorders, seizures being the most frequent one. None of the patients evidenced sequelae, 48 individuals fully recovered, five presented long-term sequelae. No event resulted in a cause of the death at the time the study was completed.
Conclusions: this is the first study that analyses the evolution of severe adverse effects reported to the National Pharmacovigilance System. It is important to sensitize the health team in terms of notifications and to strengthen the national follow-up protocols based on this experience.
References
(1) Barrios P. Inmunoprofilaxis. Vacunas. En: UdelaR. Facultad de Medicina. Departamento de Bacteriología y Virología. Temas de Bacteriología y Virología Médica. 2 ed. Montevideo: Oficina del Libro, 2006:593-5.
(2) Active and passive immunization. En: American Academy of Pediatrics. Committee on Infectious Diseases. Red Book. 30 ed. Elk Grove Village, IL: AAP, 2016: 1-101.
(3) Bases inmunológicas de las vacunas. En: Asociación Panamericana de Infectología. Manual de Vacunas de Latinoamérica. Barcelona: SLIPE, 2005:11-8.
(4) Organización Mundial de la Salud. Plan de acción mundial sobre vacunas 2011-2020. Disponible en: Disponible en: http://apps.who.int/iris/bitstream/10665/85398/ 1/9789243504988_spa.pdf Consulta: 2 noviembre 2015.
(5) Argentina. Ministerio de Salud de la Nación. Manual de Vacunación Segura: vigilancia de los eventos aparentemente atribuidos a la vacunación o inmunización (ESAVI). Bs .As.: 2012. Disponible en: http://www.msal.gov.ar/images/stories/epidemiologia/inmunizaciones/manual-vacunacion-segura-esavi.pdfConsulta: 2 noviembre 2015.
(6) Uruguay. Ministerio de Salud Pública. Vacunas. Disponible en: Disponible en: http://www.msp.gub.uy/noticia/vacunas Consulta: 2 noviembre 2015.
(7) Comisión Honoraria para la Lucha Antituberculosa y las Enfermedades Prevalentes. Programa Nacional Operativo de Inmunizaciones. Información científico técnica. Montevideo: CHLA-EP. Disponible en: http://www.chlaep.org.uy/programas-inmunizaciones-estadisticas.php Consulta: 2 noviembre 2015.
(8) Organización Panamericana de la Salud. División de Vacunas e Inmunización. Vacunación Segura: cómo enfrentar los eventos supuestamente atribuidos a la vacunación o inmunización. Washington, D.C.: 2002. Disponible en: http://www.who.int/immunization_safety/publications/aefi/en/vacunacion_segura_S.pdfConsulta: 2 noviembre 2015.
(9) Uruguay. Ministerio de Salud Pública. Vigilancia de ESAVI. Disponible en: http://www.msp.gub.uy/publicaci%C3%B3n/vigilancia-de-esavi Consulta: 2 noviembre 2015.
(10) CIOMS/WHO. Definition and Application of Terms for Vaccine Pharmacovigilance. Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Ginebra: 2012. Disponible en: Disponible en: http://www.cioms.ch/index.php/component/booklibrary/?task=view&Itemid=&id=45&catid=58 Consulta: 2 noviembre 2015.
(11) Brighton Collaboration. Available definitions. Basilea. Disponibe en: Disponibe en: https://brightoncollaboration.org/public/what-we-do/setting-standards/case-definitions/available-definitions.htmlConsulta: 2 noviembre 2015.
(12) The Office of the Chief Medical Officer of Health Communicable Disease Control Unit. Adverse events following immunization: interpretation and clinical definitions guide. 2011. Disponible en: Disponible en: http://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/CDC/HealthProfessionals/AEFIsinterpretationandclinicaldefinitionsguide.pdf Consulta: 2 noviembre 2015.
(13) Guía introductoria para la versión 16.0 del MedDRA. 2013 Disponible en: Disponible en: http://www.meddra.org/sites/default/files/guidance/file/intguide_16_0_spanish.pdf Consulta: 2 noviembre 2015.
(14) Halsey NA, Edwards KM, Dekker CL, Klein NP, Baxter R, Larussa P, et al. Algorithm to assess causality after individual adverse events following immunizations. Vaccine 2012; 30:5791-8.
(15) Clothier H, Selvaraj G, Easton M, Lewis G, Crawford N, Buttery J. Consumer reporting of adverse events following immunization. Hum Vaccin Immunother 2014; 10(12):3726-30. Disponible en: Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514059/ Consulta: 2 noviembre 2015.
(16) Government of Canada. Adverse Events Following Immunization (AEFI) Quarterly Report for 2014-Q4. Disponible en: Disponible en: http://healthycanadians.gc.ca/publications/healthy-living-vie-saine/immunization-adverse-events-2014-4-immunisation-effets-secondaires/index-eng.php Consulta: 4 julio 2016.
(17) Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Tansmissíveis. Manual de vigilância epidemiológica de eventos adversos pós-vacinação. 3 ed. Brasilia: 2014. Disponible en Disponible en www.saude.pr.gov.br/arquivos/File/-01VACINA/manual_Eventos_adversos.pdfConsulta: 2 febrero 2015.
(18) Brighton Collaboration. Resources. Basilea Disponible en: Disponible en: https://brightoncollaboration.org/public/resources.html Consulta: 2 febrero 2015.
(19) Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002; 21(3-4):298-302.
(20) Marcy SM, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004; 22:551-6. Disponible en: Disponible en: https://brightoncollaboration.org/public/resources/standards/case-definitions/main/017/link/Fever_2004_with_2007_addendum.pdf Consulta: 2 febrero 2015.
(21) Corretger Rauet JM. Fiebre y vacunas. Vacunas 2007; 8(1):30-7 Disponible en: Disponible en: https://www.invima.gov.co/images/pdf/intranet/s-medicamentos-y-productos/Memorias%20virtuales%20de%20nuestros%20objetivo/FIEBREYVACUNAS.pdf Consulta: 2 febrero 2015.
(22) Halperin S, Kohl K, Gidudu J, Ball J, Hammer S, Heath P, et al. Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:5803-20.
(23) Gobierno de Chile. Instituto de Salud Pública; González C, Saldaña A. Celulitis en el sitio de inyección posterior a la vacunación. Disponible en Disponible en http://www.ispch.cl/newsfarmacovacunas/02/images/04celulitis.pdf Consulta: 2 marzo 2016.
(24) World Health Organization. Global manual on surveillance of adverse events following immunization. 2014. Disponible en: Disponible en: http://www.who.int/vaccine_safety/publications/Global_Manual_on_Surveillance_of_AEFI.pdf Consulta: 21 marzo 2016.
(25) Centers for Disease Control and Prevention. The Vaccine Adverse Event Reporting System (VAERS). Disponible en: Disponible en: http://wonder.cdc.gov/controller/datarequest/D8 Consulta: 2 abril 2016.
(26) Hu Y, Li Q, Lin L, Chen E, Chen Y, Qi X. Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China. Clin Vaccine Immunol 2013; 20(2):211-7.
(27) Organización Mundial de la Salud. Comité Consultivo Mundial sobre Seguridad de las Vacunas, 12-13 de diciembre de 2007. Síndrome de Guillain-Barré y vacunación. Disponible en Disponible en http://www.who.int/vaccine_safety/committee/reports/Dec_2007/es/ Consulta: 21 marzo 2016.
(28) Centers for Disease Control and Prevention. Guillain-Barré syndrome and Flu Vaccine. 2015 Disponible en: Disponible en: http://www.cdc.gov/flu/protect/vaccine/guillainbarre.htm Consulta: 2 abril 2016.
(29) Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010; 10(9): 643-51.
(30) Hawken S, Kwong J, Deeks S, Crowcroft N, McGeer A, Ducharme R, et al. Simulation study of the effect of influenza and influenza vaccination on risk of acquiring Guillain-Barré syndrome. Emerg Infect Dis 2015; 21(2):224-31. Disponible en: Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313628/pdf/13-1879.pdf Consulta: 2 abril 2016.
